All In Biotech

Drug Trial Radar · NCT00003994

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

Intergroup Protocol for Treatment of Children With Hepatoblastoma

Last checked: Nov 20, 2026Latest source record: Jun 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Mar 1999

Primary completion

Oct 2007

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is most effective for children and young adults with liver cancer. This randomized phase III trial is studying giving combination chemotherapy together with amifostine to see how well it works compared to combination chemotherapy alone in treating patients with liver cancer.

Conditions

  • Childhood Hepatoblastoma
  • Recurrent Childhood Liver Cancer
  • Stage I Childhood Liver Cancer

Interventions

  • therapeutic conventional surgeryProcedure

    Undergo surgical resection

  • cisplatinDrug

    Given IV

  • vincristine sulfateDrug

    Given IV

  • fluorouracilDrug

    Given IV

  • amifostine trihydrateDrug

    Given IV

  • carboplatinDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS) ratesTime frame: Up to 8 years
  2. Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC)Time frame: Up to 8 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Oncology Group

    Arcadia, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.